Lisocabtagene maraleucel 1.1million-70million cells/ml / 1.1million-70million cells/ml dispersion for infusion vials
NHS hospitals in England used £28,512,000 of indicative cost of Lisocabtagene maraleucel 1.1million-70million cells/ml / 1.1million-70million cells/ml dispersion for infusion vials in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is up 0.0% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Lisocabtagene maraleucel 1.1million-70million cells/ml / 1.1million-70million cells/ml dispersion for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Lisocabtagene maraleucel 1.1million-70million cells/ml / 1.1million-70million cells/ml dispersion for infusion vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Leeds Teaching Hpls Nhs Trust | £3,564,000 |
| University College London Foundation Tr | £3,564,000 |
| Univ Hpl B/Ham Nhs Foundation Trust | £3,267,000 |
| University Hospital Southampton Nhs Ft | £3,267,000 |
| King's College Hpl Nhs Foundation Trust | £3,267,000 |
| Univ Hpls Bristol Nhs Foundation Trust | £2,376,000 |
| Oxford University Hospitals Nhs Ft | £1,485,000 |
| Sheffield Teaching Hospitals Nhs Trust | £1,485,000 |
| Manchester University Nhs Ft | £1,188,000 |
| The Royal Marsden Nhs Foundation Trust | £1,188,000 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.